Shengping Li

797 citations
28 papers · 565 indexed · h-index 13
Topics
Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers)Gallbladder and Bile Duct Disorders (7 papers)Pancreatic and Hepatic Oncology Research (6 papers)
Partner nations
ChinaUnited StatesTaiwan

In The Last Decade

Shengping Li

25 papers receiving 558 citations

Peers

Shengping Li
Comparison fields: 5 of 57
  • Oncology 278
  • Surgery 239
  • Pulmonary and Respiratory Medicine 126
  • Molecular Biology 122
  • Epidemiology 115
Replace Teruhisa Sonoyama with:
Teruhisa Sonoyama Japan
Niek A. Peters Netherlands
Hans‐Peter Allgaier Germany
Giorgio Frega Italy
Vittorio Branchi Germany
Takashi Seino Japan
Gerry Gin Wai Kwok China
Feiling Feng China
Nobuhiro Tsuchiya Japan
Daysha Ferrer-Torres United States
Shengping Li relative to Teruhisa Sonoyama Japan Teruhisa Sonoyama's profile →
Citations per field
00.5×3.2×
Teruhisa Sonoyama · 1×
Citations per year

Countries citing papers authored by Shengping Li

Since Specialization
Citations

This map shows the geographic impact of Shengping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengping Li more than expected).

Fields of papers citing papers by Shengping Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengping Li. The network helps show where Shengping Li may publish in the future.

Co-authorship network of co-authors of Shengping Li

This figure shows the co-authorship network connecting the top 25 collaborators of Shengping Li. A scholar is included among the top collaborators of Shengping Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengping Li. Shengping Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 5
3 0
4 8
5 10
6 0
7 12
8 11
9 4
10 7
11 16
12 16
13 36
14 28
15 32
16 19
17 10
18 5
19 86
20 41

About Shengping Li

Shengping Li is a scholar working on Hepatology, Oncology and Surgery, having authored 28 papers that have together received 565 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Gallbladder and Bile Duct Disorders (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). The work is most often cited by research in Hepatology (101 citations), Oncology (278 citations) and Cancer Research (105 citations). Shengping Li has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Yize Mao, Guo‐He Lin, Xiang‐Ming Lao, Xiaojun Lin, Jianlin Chen, Zeyu Shuang, Chaobin He, Xin Huang, Jun Wang and Yongcheng Liu. Their work appears in journals such as Journal of Biological Chemistry, Frontiers in Immunology and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026